Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
about
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate CancerAbiraterone in the treatment of metastatic castration-resistant prostate cancerUse of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancerQuo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapiesRationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancerGlucocorticoids and prostate cancer treatment: friend or foe?Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directionsEnzalutamide: an evidence-based review of its use in the treatment of prostate cancerNovel drugs targeting the androgen receptor pathway in prostate cancer.Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel-an Indirect ComparisonAndrogen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathwayCYP17A1 inhibitors in castration-resistant prostate cancerEnzalutamide for patients with metastatic castration-resistant prostate cancerConversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.Tumor clone dynamics in lethal prostate cancerGlucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancerAndrogen pathway resistance in prostate cancer and therapeutic implicationsMinireview: Androgen metabolism in castration-resistant prostate cancer.The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer.Enzalutamide (formerly MDV3100) as a new therapeutic option for men with metastatic castration-resistant prostate cancerMolecular pathogenesis and progression of prostate cancerAndrogen-responsive serum response factor target genes regulate prostate cancer cell migration.Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer.AKR1C3 as a target in castrate resistant prostate cancerAndrogen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis.First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.Advances in androgen receptor targeted therapy for prostate cancerCellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.The osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer.Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefitA novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis.Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer.Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.
P2860
Q26751237-A385DDEF-517B-4E92-8D1B-10A8AB43652AQ26853635-054ADB40-8156-413C-82A0-AA2F02887DC1Q26865701-2FE438DB-C511-445A-926F-DEDBC71F532FQ27011642-EF442B79-ACD7-41EF-BD2A-8BE5B5B9B358Q27028084-B5C2EF36-07BB-4AB4-B9D0-E2F82924D6C3Q33621387-3B9096A0-C1E3-4113-9045-FA63B7B04E0AQ33621403-57E4CFFB-C755-41BF-9EDD-DB79BD427541Q33775717-46934E6B-0E01-4B73-B0C7-CE8D6B60EB1CQ34324736-DDF9DB67-3379-428B-A6D7-11A0C01B35BBQ34339501-31636737-986C-450E-B3B7-6D77CA0DCE27Q34395777-2F1127BB-D093-45B0-83B2-EEFB0D38A96BQ34412589-649EC8BA-85CF-4948-90F2-E9D9D3E9318CQ34444867-3AA962B0-67E4-47D0-831D-81B259878954Q34456638-433F7033-7DD6-4EC6-B5EB-F2AA860D381BQ34475171-D5549187-5428-459F-90F3-B5910E5F8483Q34478734-E86C2343-9057-49F6-9ED2-C7370DC9333AQ34522279-65766CEA-18D0-40C0-A1DF-355120CD099FQ34525556-A80C03B0-4A48-4DB4-BB0E-ED78AF98A9A3Q35575930-63C6CCA4-6AB5-4A30-8676-D0A79A01D8D4Q35631971-A0E52EEE-9B3A-4938-A0F4-49BF4AEF7739Q36416370-AA4116B6-EBCA-4CC9-9839-6EA47A5BA028Q36789277-43FE501F-A520-45B8-AB68-AD3E26586F0CQ36880048-AA2751B8-8513-4251-A3DC-DC78D996D23BQ37037628-07218715-61D4-4AF0-BC37-3220E7985932Q37055715-6DEB2ADE-FD45-4FB8-8D23-E667023425DAQ37065350-2B607CAE-8CC7-41A8-8F2E-F8B130C49659Q37076775-8EEA3584-C4F8-4D76-B23F-AF3FC7CA9C7DQ37248854-18876C2C-1393-4AE2-9CFD-1898AB5562BBQ37269053-7E6F92CE-580A-4ACE-A85C-4854509A2B30Q37311904-93D6E8B6-4C4C-4D72-A8F3-F69B1512C38EQ37323018-DAFD9FB2-BF06-4DDF-9FDE-CDF5CF96DB3DQ37337217-26DBDDD6-DD2F-493E-BCB9-39952A67DA84Q37457995-F3171DE9-959D-43F4-A065-060F12CE0FF4Q37615017-64559AB1-C969-499D-A465-5E10670B2ECEQ37620953-1001EFA9-52A8-4C45-AA2C-A923950F416DQ37710823-986FF86D-22F8-404F-89CE-ECA239E3BB7AQ38181005-17CA349D-E184-4DC5-BE2C-10F609F9CD5CQ38183819-B893DE56-9C48-4E98-B1E3-EDF7445320A6Q38184622-8D3341A6-AB6E-4A3D-917A-6E2FE6428672Q38205964-64262BDD-531C-4B23-8560-C588DDB1BD25
P2860
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Interactions of abiraterone, e ...... ure or combining with MDV3100.
@en
Interactions of abiraterone, e ...... ure or combining with MDV3100.
@nl
type
label
Interactions of abiraterone, e ...... ure or combining with MDV3100.
@en
Interactions of abiraterone, e ...... ure or combining with MDV3100.
@nl
prefLabel
Interactions of abiraterone, e ...... ure or combining with MDV3100.
@en
Interactions of abiraterone, e ...... ure or combining with MDV3100.
@nl
P2093
P2860
P50
P1433
P1476
Interactions of abiraterone, e ...... ure or combining with MDV3100.
@en
P2093
Ai Chiin Lim
Angela E Taylor
Anna Wingate
Carmel Pezaro
Colin W Hay
Iain J McEwan
Jane Goodall
Johann S de Bono
Juliet Richards
Karolina Nowakowska
P2860
P304
P356
10.1158/0008-5472.CAN-11-3980
P407
P577
2012-03-12T00:00:00Z